KainosMed Signs Joint Research Agreement with AI Drug Development Company Dr. Noah Biotech

[Asia Economy Reporter Yoo Hyun-seok] KainosMed, which is pursuing a merger listing with Hana Financial No.11 SPAC, is embarking on new drug development using an artificial intelligence (AI) platform.

KainosMed announced on the 25th that it has signed a joint research and development agreement with Dr. Noah Biotech, an AI-based new drug development specialized company.

Under this agreement, Dr. Noah Biotech will provide the structures of substances optimized for target diseases using its AI platform, and based on this, KainosMed plans to derive new drug candidate substances through substance synthesis and optimization.

KainosMed is focusing on developing treatments for intractable diseases such as Parkinson's disease and AIDS. The AIDS treatment KM-023 is currently undergoing Phase 3 clinical trials in China. KM-819 plans to start Phase 2 clinical trials this year in the U.S. as a Parkinson's disease treatment and in Korea as a multiple system atrophy treatment. The company has research pipelines for anticancer and antiviral treatments and plans to actively utilize Dr. Noah Biotech's AI-based ARK platform to build new pipelines.

Dr. Noah Biotech possesses the AI-based ARK platform capable of integrative analysis of literature information, genomic data, and structural information. This technology is used to derive new drug candidate substances or develop new combination drugs that show superior synergistic effects compared to single drugs. In this joint research, the ‘AI Virtual Compound Screening’ system installed on the ARK platform will be used to predict new drug structures.

Since KainosMed and Dr. Noah Biotech have already been discussing mutual joint research and development for the past year, they plan to specify the scope of the first phase of joint new drug development research starting from this agreement.

A KainosMed official said, “We will focus our research capabilities to not only discover innovative new drug candidates using Dr. Noah Biotech’s AI platform technology but also to achieve results in technology export.”

This content was produced with the assistance of AI translation services.